Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that Richard Godfrey, BergenBio’s chief executive officer, will present at the H.C. Wainwright 21st Annual Global Life Sciences Conference today, September 10, 2019.
Date: Tuesday, September 10, 2019
Time: 5.15pm CEST
Location: Lotte New York Palace Hotel, New York
The presentation slides will be available on www.bergenbio.com in the investor section at the time of the